Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10470199rdf:typepubmed:Citationlld:pubmed
pubmed-article:10470199lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:10470199lifeskim:mentionsumls-concept:C0007134lld:lifeskim
pubmed-article:10470199lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:10470199lifeskim:mentionsumls-concept:C0034348lld:lifeskim
pubmed-article:10470199lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:10470199pubmed:issue4Alld:pubmed
pubmed-article:10470199pubmed:dateCreated1999-9-28lld:pubmed
pubmed-article:10470199pubmed:abstractTextThe evaluate a potential tumor marker for RCC. Tumor formation is generally linked to an expansion of glycolytic phosphometabolite pools and aerobic glycolyticflux rates. To achieve this, tumor cells generally overexpress a special glycolytic isoenzyme, termed pyruvate kinase type M2. To establish the expansion of phosphometabolite pools pyruvate kinase switches between a tetrameric form with high phosphoenol-pyruvate (PEP) affinity and a dimeric form with a lower PEP affinity. The dimeric form is predominant in all tumors that have been investigated and has been termed TuM2Pk.lld:pubmed
pubmed-article:10470199pubmed:languageenglld:pubmed
pubmed-article:10470199pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10470199pubmed:citationSubsetIMlld:pubmed
pubmed-article:10470199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10470199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10470199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10470199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10470199pubmed:statusMEDLINElld:pubmed
pubmed-article:10470199pubmed:issn0250-7005lld:pubmed
pubmed-article:10470199pubmed:authorpubmed-author:BichlerK HKHlld:pubmed
pubmed-article:10470199pubmed:authorpubmed-author:FeinAAlld:pubmed
pubmed-article:10470199pubmed:authorpubmed-author:PetriEElld:pubmed
pubmed-article:10470199pubmed:authorpubmed-author:WechselH WHWlld:pubmed
pubmed-article:10470199pubmed:issnTypePrintlld:pubmed
pubmed-article:10470199pubmed:volume19lld:pubmed
pubmed-article:10470199pubmed:ownerNLMlld:pubmed
pubmed-article:10470199pubmed:authorsCompleteYlld:pubmed
pubmed-article:10470199pubmed:pagination2583-90lld:pubmed
pubmed-article:10470199pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:meshHeadingpubmed-meshheading:10470199...lld:pubmed
pubmed-article:10470199pubmed:articleTitleMarker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).lld:pubmed
pubmed-article:10470199pubmed:affiliationDepartment of Urology, Eberhard-Karls-University, Tuebingen, Germany.lld:pubmed
pubmed-article:10470199pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10470199lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10470199lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10470199lld:pubmed